Transoral robotic surgery for oropharyngeal squamous cell carcinoma in the era of human papillomavirus

Transoral robotic surgery for oropharyngeal squamous cell carcinoma in the era of human... INTRODUCTIONIn the United States, 16 420 patients were diagnosed with oropharyngeal squamous cell carcinoma (SCC) in 2015, and the incidence is increasing steadily due to the human papillomavirus (HPV) epidemic. This viral infection of oropharyngeal crypts is the precursor to oncogenic transformation in >60% of oropharyngeal SCC cases, in contrast to the previous paradigm of oropharyngeal SCC induction from tobacco exposure, with distinctive molecular, clinicopathologic, and prognostic characteristics. The HPV‐negative oropharyngeal SCC displays 25% lower 3‐year overall survival (OS; 57% vs 82%; P < .001) compared to HPV‐positive disease, with HPV status being the single most influential prognostic factor for patients with oropharyngeal SCC. Enhanced radiosensitivity and antitumor immune response potentially explain the improved outcomes in HPV‐positive oropharyngeal SCC, which potentially justifies tailoring treatment based on this marker. Indeed, treatment deintensification is currently being tested in HPV‐positive oropharyngeal SCC through elimination/substitution of traditional cisplatin chemosensitization and/or radiation dose reduction.Along with the oropharyngeal SCC epidemiologic shift, advances in surgical technique reintroduced transoral laser microsurgery and introduced transoral robotic surgery (TORS) into the management paradigm. In contrast to the open surgical approach, these minimally invasive surgeries eliminate the mandibulotomy or pharyngotomy that resulted in significant morbidity with traditional surgical approaches. Primary approaches using TORS, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Head & Neck: Journal for the Sciences & Specialties of the Head and Neck Wiley

Transoral robotic surgery for oropharyngeal squamous cell carcinoma in the era of human papillomavirus

Loading next page...
 
/lp/wiley/transoral-robotic-surgery-for-oropharyngeal-squamous-cell-carcinoma-in-B6oIaCMAw3
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
© 2018 Wiley Periodicals, Inc.
ISSN
1043-3074
eISSN
1097-0347
D.O.I.
10.1002/hed.25036
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONIn the United States, 16 420 patients were diagnosed with oropharyngeal squamous cell carcinoma (SCC) in 2015, and the incidence is increasing steadily due to the human papillomavirus (HPV) epidemic. This viral infection of oropharyngeal crypts is the precursor to oncogenic transformation in >60% of oropharyngeal SCC cases, in contrast to the previous paradigm of oropharyngeal SCC induction from tobacco exposure, with distinctive molecular, clinicopathologic, and prognostic characteristics. The HPV‐negative oropharyngeal SCC displays 25% lower 3‐year overall survival (OS; 57% vs 82%; P < .001) compared to HPV‐positive disease, with HPV status being the single most influential prognostic factor for patients with oropharyngeal SCC. Enhanced radiosensitivity and antitumor immune response potentially explain the improved outcomes in HPV‐positive oropharyngeal SCC, which potentially justifies tailoring treatment based on this marker. Indeed, treatment deintensification is currently being tested in HPV‐positive oropharyngeal SCC through elimination/substitution of traditional cisplatin chemosensitization and/or radiation dose reduction.Along with the oropharyngeal SCC epidemiologic shift, advances in surgical technique reintroduced transoral laser microsurgery and introduced transoral robotic surgery (TORS) into the management paradigm. In contrast to the open surgical approach, these minimally invasive surgeries eliminate the mandibulotomy or pharyngotomy that resulted in significant morbidity with traditional surgical approaches. Primary approaches using TORS,

Journal

Head & Neck: Journal for the Sciences & Specialties of the Head and NeckWiley

Published: Jan 1, 2018

Keywords: ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off